A 10-day implementation has given the team at Abarca Health the opportunity to challenge how they manage implementations in general.
When Abarca Health took over as the full-service PBM for Vital, the Medicaid program managed by the Puerto Rico Health Insurance Administration (ASES), it faced a challenge. The PBM needed to implement the program in just 10 days. But the company was able to meet the challenge and transition essential services, including claims processing, formulary management, and network contracting and payments management, with no disruption in benefits for 1.3 million Medicaid beneficiaries.
Adriana Ramirez
A typical implementation takes about nine months to a year, said Adriana Ramirez, Abarca’s chief operating officer. “For a complex benefit and complex client, we’re talking about multiple months of work,” she said in an interview with Formulary Watch. “There is a lot of the heavy lifting around the configuration work and data exchange, or they would not be able to process claims appropriately.”
A team of about 30 people came together onsite in Puerto Rico, working 18-hour days, to complete the implementation on time. They prioritized data exchange and proper mapping of files.
Ramirez said one of the challenges they faced in such a shortened timeframe was training the more than 200 people from the various managed care organizations who would be using the system. “The team got very creative, creating basic a Q&A and doing very tailored training to specific users,” she said. “We had multiple people physically at the managed care organizations to coach them on the system.”
To reach members, Abarca worked with local pharmacies. The Medicaid program in Puerto Rico serves members through 900 community pharmacies with two or three associations that represent them. Once the implementation was completed, Abarca’s claims team monitored the call center and daily rejected claims, but Ramirez said things went smoothly.
While every implementation is different, she said there are learnings that can be had from this experience. “We’ve seen what’s possible. It was a big sacrifice, but it turned out positively. Going forward, I’m questioning the status quo about how we’ve done things. It’s given us the opportunity to be able to challenge how we manage implementations in general.”
Related: A PBM that Takes on Financial Risk
Abarca is a PBM with a net cost pricing solution, which guarantees the net cost of drugs, including specialty medications, by offering a fixed, per-script cost for a plan’s entire population. This pricing model, Assura, recently was awarded the 2022 PBMI Excellence Award.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More